At a glance
- Originator AstraZeneca
- Class Antidementias; Antiulcers; Antivirals; Calcium regulators; Macrolides; Neuroprotectants; Osteoporosis therapies
- Mechanism of Action Proton pump inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Gastrointestinal disorders; Influenza virus infections; Postmenopausal osteoporosis